– Bloomberg
HC Wainwright & Co. Maintains Buy on Axcella Health, Raises Price Target to $10
HC Wainwright & Co. analyst Ed Arce maintains Axcella Health (NASDAQ:AXLA) with a Buy and raises the price target from $8 to $10.
Related Posts
Actinium Pharma Highlights Six Abstracts Accepted For Oral And Poster Presentation At The SNMMI 2023 Annual Meeting
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details the six abstracts accepted for oral and poster presentation at the upcoming
Analyst Says M&A Could Be A Negative Catalyst For This Aesthetic Company
Needham has downgraded InMode Ltd (NASDAQ:INMD) from Buy to Hold with no price target. The analyst writes that the 1Q23 aesthetics patient…
Apple, Coinbase And 3 Stocks To Watch Heading Into Friday
With US stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: